首页> 外文期刊>Hematological oncology >Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review
【24h】

Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review

机译:程序性死亡1和B和T淋巴细胞减毒免疫受体及其与恶性T淋巴细胞增生性疾病的关系:简要综述

获取原文
获取原文并翻译 | 示例
           

摘要

Malignant T-cell lymphoproliferative diseases are relatively rare. T cells are activated through the T-cell receptor with the aid of costimulating molecules that can be either excitatory or inhibitory. Such pathways have been also implicated in mechanisms of malignant T-cell lymphoproliferative diseases' persistence and relapse by circumventing immune responses. To date, three major immunoinhibitory molecules have been recognized, namely programmed cell death-1 (PD-1), B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte antigen 4 (CTLA-4). Although CTLA-4 is considered the gatekeeper' of immune tolerance, PD-1 negatively regulates immune responses broadly, whereas BTLA activation has been shown to inhibit CD8+ cancer-specific T cells. Both PD-1 and BTLA downregulate proximal T-cell receptor signalling cascade and are involved in immune evasion of leukaemias and lymphomas, even after allogeneic stem cell transplantation. These immunoregulatory molecules can have seemingly a synergistic effect on weakening the immune response of patients with haematological malignancies, and their manipulation represents a very active field of preclinical as well as clinical interest. Copyright (c) 2013 John Wiley & Sons, Ltd.
机译:恶性T细胞淋巴组织增生性疾病相对罕见。 T细胞在协同刺激分子的刺激下通过T细胞受体活化。通过绕过免疫反应,这种途径也与恶性T细胞淋巴组织增生性疾病的持续和复发机制有关。迄今为止,已经认识到三种主要的免疫抑制分子,即程序性细胞死亡1(PD-1),B和T淋巴细胞减毒剂(BTLA)和细胞毒性T淋巴细胞抗原4(CTLA-4)。尽管CTLA-4被认为是免疫耐受的守门员,但PD-1广泛地负调节免疫反应,而BTLA激活已显示抑制CD8 +癌症特异性T细胞。即使同种异体干细胞移植后,PD-1和BTLA都下调了近端T细胞受体信号传导级联,并且参与了白血病和淋巴瘤的免疫逃逸。这些免疫调节分子在减弱血液系统恶性肿瘤患者的免疫反应方面似乎具有协同作用,其操纵代表了临床前和临床上非常活跃的领域。版权所有(c)2013 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号